Our mission: to redefine the standard of care in hair loss

AGA is common, but its prevalence is easy to underestimate. Up to 50% of men and up to 40% of women are affected. By age 50, half of all men show signs of AGA; by age 70, prevalence reaches up to 80% in men and up to 50% in women, with a marked increase after menopause.

A condition this common deserves continued scientific attention.

Sources: Landells I, et al. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. J Cutan Med Surg. 2025;29(5 Suppl):5S-14S. doi:10.1177/12034754251368849; Bhoyrul B, et al. Expanding the therapeutic landscape of minoxidil for androgenetic alopecia. Front Pharmacol. 2026;16:1718208. doi:10.3389/fphar.2025.1718208

#AndrogeneticAlopecia#AGA#HairLoss#HairScience#Dermatology

Hair loss is visible but its psychological impact isn’t. Research is increasingly showing that the experience of androgenetic alopecia can extend beyond the scalp. This World Mental Health Day, we’re recognizing the full picture.

Reference: Kong Y, Shang Y, Zhang L. Front Psychiatry. 2025;16:1705957.

#WorldMentalHealthDay#AndrogeneticAlopecia#AGA#HairLoss#MentalHealth#Dermatology

Our new website is live. Explore Triple Hair’s mission, our research approach, and the science behind our ongoing work in androgenic alopecia.

Discover our commitment to advancing clinical research, combination therapy approaches, and innovation in hair loss science.

Visit us at triplehair.ca

#TripleHair#Biopharma#ClinicalResearch#AGA#HairLossResearch#Dermatology#Innovation

Hair loss is often described as if the follicle simply “stops growing.”

The biology is more nuanced. In androgenetic alopecia, the changes happen gradually, across repeated hair-growth cycles. Understanding what is happening at the follicular level helps explain why AGA is a progressive condition and why the biology behind hair loss matters when studying potential treatments.

This serves as the basis for grasping the follicle and pursuing further research into answers. 

#AndrogeneticAlopecia#AGA#HairScience#HairBiology#HairLossResearch#Dermatology#TrichologyReference: Chen S, Li L, Ding W, Zhu Y, Zhou N. *Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.* Drug Des Devel Ther. 2025;19:7349–7363. doi:10.2147/DDDT.S542000.

Androgenetic alopecia affects both men and women.

Research suggests that up to 50% of women may experience androgenetic alopecia by age 70. Female pattern hair loss can differ in its presentation and characteristics, making it an important area of ongoing research.

Understanding who is affected, how hair loss presents, and the biology behind it helps build a clearer picture of androgenetic alopecia.

#TripleHair#AndrogeneticAlopecia#HairScience#HairLossResearch#WomensHealth#Dermatology#ClinicalResearch

We’re heading to Vienna for EADV Congress 2026, September 30–October 3.

We’re looking forward to connecting with dermatologists, researchers, and industry colleagues and exchanging perspectives on the evolving science of androgenic alopecia.

If you’ll be attending, let’s connect. See you in Vienna. 

#EADV2026#EADV#Dermatology#AndrogenicAlopecia#AGA#HairLossResearch#ClinicalResearch#TripleHair

The most common form of hair loss, and still one of the most undertreated.

Androgenetic alopecia affects up to 80% of men and up to 50% of women by age 70 (Bhoyrul et al., 2026), with real consequences for confidence, identity, and quality of life.

One of the most common conditions in medicine remains one of the most under-researched. That gap deserves serious science.

#AndrogeneticAlopecia#HairLoss#DiseaseAwareness#QualityOfLife#Dermatology

A recent review highlights that approximately 60% of patients using topical minoxidil may see no visible improvement. For a condition affecting millions of people, treatment response remains an important area of ongoing research. This is not about dismissing established therapies. It is about understanding where the evidence stands today, where limitations remain, and where scientific questions still need answers.

In research, an unmet need is often where the most important questions begin.

Reference: Bhoyrul B, et al. Expanding the therapeutic landscape of minoxidil for androgenetic alopecia.
Front Pharmacol. 2026;16:1718208.

#AndrogenicAlopecia#ClinicalResearch#HairLoss#AGA#Dermatology#PatientOutcomes

Androgenic alopecia involves multiple biological processes. That complexity has led researchers to explore whether therapies with different mechanisms can be combined.

Published research has begun investigating combination approaches in AGA, including combinations of topical minoxidil and topical finasteride but combining therapies is only the beginning. Researchers still need to understand whether a combination is safe, effective, and supported by clinical evidence.

The science is evolving, and every study adds another piece to the picture.

#TripleHair#CombinationTherapy#AndrogenicAlopecia#AGA#HairLossResearch#ClinicalResearch#Dermatology#HairScience

AGA is a complex biological condition, involving more than one process within the hair follicle raising an interesting research question: could therapies with different mechanisms be studied together? 

Published research has begun exploring combination approaches in AGA, including topical minoxidil and topical finasteride.

The goal of research is not to assume the answer, but to investigate it.

#TripleHair#HairScience#CombinationTherapy#AndrogenicAlopecia#AGA#HairLossResearch#ClinicalResearch#Dermatology